China Biologic Products Inc (CBPO) : Indus Capital Partners scooped up 175,918 additional shares in China Biologic Products Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 12, 2016. The investment management firm now holds a total of 378,518 shares of China Biologic Products Inc which is valued at $47,557,002.China Biologic Products Inc makes up approximately 5.92% of Indus Capital Partners’s portfolio.
Other Hedge Funds, Including , Parametric Portfolio Associates boosted its stake in CBPO in the latest quarter, The investment management firm added 22,534 additional shares and now holds a total of 56,887 shares of China Biologic Products Inc which is valued at $7,147,283. China Biologic Products Inc makes up approx 0.01% of Parametric Portfolio Associates’s portfolio.New York State Common Retirement Fund boosted its stake in CBPO in the latest quarter, The investment management firm added 12,583 additional shares and now holds a total of 14,793 shares of China Biologic Products Inc which is valued at $1,858,593.Ubs Asset Management Americas Inc boosted its stake in CBPO in the latest quarter, The investment management firm added 6,509 additional shares and now holds a total of 201,265 shares of China Biologic Products Inc which is valued at $25,558,642. China Biologic Products Inc makes up approx 0.03% of Ubs Asset Management Americas Inc’s portfolio. Lmr Partners Llp sold out all of its stake in CBPO during the most recent quarter. The investment firm sold 10,970 shares of CBPO which is valued $1,309,599. Capital Fund Management S.a. added CBPO to its portfolio by purchasing 2,522 company shares during the most recent quarter which is valued at $296,839. China Biologic Products Inc makes up approx 0.01% of Capital Fund Management S.a.’s portfolio.
China Biologic Products Inc opened for trading at $112.2 and hit $113.5 on the upside on Monday, eventually ending the session at $112.08, with a gain of 0.05% or 0.06 points. The heightened volatility saw the trading volume jump to 2,68,765 shares. Company has a market cap of $3,014 M.
On the company’s financial health, China Biologic Products Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.08 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $1.18. The company had revenue of $91.42 million for the quarter, compared to analysts expectations of $87.58 million. The company’s revenue was up 15.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.06 EPS.
China Biologic Products Inc. (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research development manufacturing and sales of human plasma-based biopharmaceutical products in China. China Biologic has a product portfolio with over 20 different dosage forms of plasma products. The Company’s principal products are human albumin and immunoglobulin for intravenous injection (IVIG). China Biologic operates its business through two subsidiaries namely Shandong Taibang Biological Products Co. Ltd. and Guizhou Taibang Biological Products Co. Ltd. The Company also holds an interest in Xi’an Huitian Blood Products Co. Ltd. a plasma products company. Its products include human albumin human immunoglobulin IVIG thymopolypeptides injection human hepatitis B immunoglobulin human rabies immunoglobulin human tetanus immunoglobulin placenta polypeptide Factor VIII and human prothrombin complex concentrate (PCC).